چارچوب بررسی توسعه صنعت داروسازی در کشورهای در حال توسعه: شواهد از ایران

اختصاصی از یارا فایل چارچوب بررسی توسعه صنعت داروسازی در کشورهای در حال توسعه: شواهد از ایران دانلود با لینک مستقیم و پرسرعت .

Abstract

Background: The pharmaceutical market is a complex market due to its complicated supply chain and the extent of government regulations in all aspects of the trade life cycle of drug development. Considering the importance of pharmaceutical for society and the relevant trend of globalization, managing pharmaceutical industry effectively and efficiently is vital, particularly in developing countries.

Methodology: The present study determines factors affecting the development of the Iranian pharmaceutical industry, based on pharmaceutical mangers` point of view. In this study we assessed Managers` perspective about key internal & external factors affecting the development of pharmaceutical industry. Finally, their perspective about the solutions for development of pharmaceutical industry was assessed. Accordingly, a self-designed questionnaire was sent to 65 managers at Tamin Pharmaceutical Investment Company (TPICO), of which 51 managers answered the questionnaires.

Results: Most managers believed generic scheme reflect negatively on the development of the pharmaceutical industry, and that external factors have a great impact on its improvement.  They believed that branded- generic transition along with supporting regulations, investment in R&D, and joint venture with foreign companies will improve the pharmaceutical industry.

Conclusion: There were reasonable grounds for generic scheme implementation, but focus on saving and domestic production diminished the industry`s competitiveness. This along with negative effects of external factors weakened the pharmaceutical industry. Incentives for improving the pharmaceutical industry`s development should be considered. The most important one is to create a condition that encourages companies to improve their situation. On the other hand, supporting regulations and investment in infrastructure, strengthening R&D units, and also private sector reinforcement should be considered.